Summary of the primer on tumor immunology and the biological therapy of cancer
- PDF / 156,656 Bytes
- 5 Pages / 610 x 792 pts Page_size
- 81 Downloads / 144 Views
BioMed Central
Open Access
Editorial
Summary of the primer on tumor immunology and the biological therapy of cancer Yufeng Li1, Shujuan Liu1, Kim Margolin2 and Patrick Hwu*1 Address: 1Department of Melanoma Medical Oncology, the University of Texas, M. D. Anderson Cancer Center, Houston, TX, USA and 2Department of Medicine Division of Oncology, University of Washington, Seattle, WA, USA Email: Yufeng Li - [email protected]; Shujuan Liu - [email protected]; Kim Margolin - [email protected]; Patrick Hwu* - [email protected] * Corresponding author
Published: 28 January 2009 Journal of Translational Medicine 2009, 7:11
doi:10.1186/1479-5876-7-11
Received: 27 December 2008 Accepted: 28 January 2009
This article is available from: http://www.translational-medicine.com/content/7/1/11 © 2009 Li et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract The International Society for Biological Therapy of Cancer (iSBTc) is one of the "premier destinations for interaction and innovation in the cancer biologics community". It provides a primer course each year during the annual meeting to address the most important areas of tumor immunology and immunotherapy. The course has been given by prominent investigators in the area of interest, covering the core principles of cancer immunology and immunotherapy. The target audience for this program includes investigators from academic, regulatory, and biopharmaceutical venues. The program goal is to enable the attendees to learn the current status and the most recent advances in biologic therapies, and to leverage this knowledge towards the improvement of cancer therapy. The 2008 immunologic primer course was held on October 30 at the 23rd Annual meeting of iSBTc in San Diego, CA. Nine internationally renowned investigators gave excellent presentations on different topics. The topics covered in this primer included: (1) cytokines in cancer immunology; (2) anti-angiogenic therapy; (3) end stage: immune killing of tumors; (4) blocking T cell checkpoints; (5) approach to identification and therapeutic exploitation of tumor antigens; (6) T regulatory cells; (7) adoptive T cell therapy; (8) immune monitoring of cancer immunotherapy; and (9) immune adjuvants. We summarized the topics in this primer for public education. The related topic slides and schedule can be accessed online http://www.isbtc.org/ meetings/am08/primer08.
Cytokines in cancer immunology The development of anti-cancer cytokines is an active area for investigators in the field of cancer immunotherapy. Dr. Mario Sznol, MD (Yale University School of Medicine) gave a comprehensive topic on the application of cytokines in cancer immunotherapy. Both immune or non-immune cells can be the focus of biological rationals for cytokine therapy, including: 1)
Data Loading...
